Replies to post #606872 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Failure to understand how clinical trials work.

Correct, the hedge fund social media army fails to understand that when you take DCVax-L after recurrence YOU ARE NO LONGER IN THE PLACEBO ARM AS YOU HAVE TAKEN DCVax-L.. In fact, the crossover, mandated by the FDA, led to never before seen survival numbers in rGBM. Now DCVax-L will be approved for nGBM and rGBM. Thanks for pointing this out.

have a good one friend. by.

[Dr Bala]

Checkmating 101: Fabrications in the post based on lack of understanding of the crossover results in the JAMA article.

[Hspooner]

Discovery can be a bitch exwannabe!!! LOL..LOL…LOL…

[meirluc]

The 99 were randomized to "an intent to crossover group" of whom 64 crossed over, 29 did not and 6 dropped out of the trial. The 92 remaining in the "intend to crossover group" had an mOS that far exceeded the placebo groups and even exceeded the mOS of the DCVax-L trial's treatment group.

Dr. Liau implied in one of her presentations during the Q+A period that the 29 permanent placebos had an mOS that was most likely lower than that of the placebos. It is easy to deduce that the remaining 64 crossovers in the group of 99 had an extremely long mOS.

Conclusion: DCVax-L treatment after progression is very efficaceous and greatly increases the mOS.